Convincingly low levels of infections with long-term tildrakizumab TrialreSURFACE 1 and 2 ConferenceAAD VMX 2021 7 June, 2021 13:15
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome Presented ByDr Alice Gottlieb, Tufts University School of Medicine, USA TrialreSURFACE 1 and 2 ConferenceEADV 2019 9 October, 2019 17:28